Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
Tezosentan in Pulmonary Arterial Hypertension
Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With Stable, Chronic Pulmonary Arterial…
- Trial name
- NCT01077297
- Testing
- Tezosentan
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 3 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)
Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension
Hypothesis: The small molecule and metabolic modulator Dichloroacetate (DCA) is safe, tolerated as a potential therapy in patients with moderate or severe Pulmonary Arterial Hypertension (PAH).
- Trial name
- NCT01083524
- Testing
- Dichloroacetate Sodium
- Where
- 2 sites in Canada, United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Alberta
Pulmonary Hypertension
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
This pilot, non-interventional, company-sponsored, multi-center study documents observational data on patients under routine treatment of Pulmonary Arterial Hypertension (PAH) with inhaled iloprost (using I-Neb device for the…
- Trial name
- COMPHI (NCT01894035)
- Testing
- Iloprost (Ventavis, BAYQ 6256)
- Where
- Portugal
- Volunteers
- 13 people
- Sponsor
- Bayer
Pulmonary Hypertension, Metal Poison
Study Roles of Heavy Metals and Essential Metal Dyshomeostasis in Pulmonary Arterial Hypertension Patients
Investigators plan to recruit 50 PAH patients from UofL PAH Clinic, with various degrees of severity (25 intermediate risk patients and 20 high risk patients) and 10 age and gender matched controls.
- Trial name
- NCT04756076
- Testing
- Metal level measurements
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Jiapeng Huang
Pulmonary Arterial Hypertension
Inhaled Treprostinil for PAH: Open-label Extension
Open-label extension of RIN-PH-302.
- Trial name
- INTREPID - OL (NCT01557660)
- Testing
- inhaled treprostinil
- Sponsor
- United Therapeutics
Pulmonary Hypertension, Quality of Life
Quality of Life Questionnaire in Pulmonary Hypertension EMPHASIS-10: Brazilian Adaptation and Validation
Pulmonary hypertension (PH) is a severe and heterogeneous condition associated with poor prognosis and significant impairment in quality of life.
- Trial name
- EMPHASIS-10-BR (NCT07822997)
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Hypertension, Pulmonary
Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) Subjects
GlaxoSmithKline (GSK) is embarking on a clinical program to assess the treatment of PAH with an Angiotensin converting enzyme 2 (ACE2).
- Trial name
- NCT03304548
- Testing
- Telephone concept elicitation interview
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Systemic Sclerosis, Pulmonary Arterial Hypertension
Extracellular Vesicle Dynamics Predicting Vascular Complications and Treatment Response in Systemic Sclerosis
Systemic sclerosis is a multisystem autoimmune disease characterized by vascular dysfunction, immune dysregulation, and progressive tissue fibrosis.
- Conditions
- Systemic Sclerosis, Pulmonary Arterial Hypertension, Digital Ulcers, Vascular Complications
- Trial name
- EVOLVE-SSc (NCT07717060)
- Testing
- Blood sampling, nailfold capillaroscopy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Pulmonary Arterial Hypertension
Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat)
This Study evaluates the pharmacokinetic (PK) profile of different zamicastat doses in Pulmonary arterial hypertension (PAH) patients to find the most promising therapeutic dosage range for the treatment of PAH disease
- Trial name
- NCT04316143
- Testing
- Oral zamicastat
- Where
- 13 sites in Austria, Germany and 5 more
- Volunteers
- 33 people
- Sponsor
- Bial - Portela C S.A.
Pulmonary Arterial Hypertension
Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension
The development of selexipag for intravenous administration will be useful to avoid treatment interruptions in patients with pulmonary arterial hypertension (PAH) already treated with selexipag administered orally as tablets…
- Trial name
- NCT03187678
- Testing
- i.v. selexipag, oral selexipag (Uptravi)
- Where
- 8 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- Actelion
Secondary Pulmonary Arterial Hypertension, Sickle Cell Disease
Pulmonary Hypertension in Patients With Sickle Cell Disease in Nigeria
This study will explore how people with sickle cell disease (SCD) develop a complication called pulmonary hypertension (PHTN), a serious disease in which blood pressure in the lungs is higher than normal.
- Conditions
- Secondary Pulmonary Arterial Hypertension, Sickle Cell Disease, Pulmonary Hypertension
- Trial name
- NCT00367523
- Where
- Nigeria
- Volunteers
- 308 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Artery Hypertension
Vascular Subphenotypes of Lung Disease in HIV & COPD
This study is looking for high blood pressure in the lungs (Pulmonary artery hypertension PAH) in HIV and COPD patients.
- Trial name
- VAST (NCT01581086)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pittsburgh
Diabetes Mellitus, Hypertension
Evidence-based Laboratory Test Order Sets in Primary Care
Cluster randomised controlled trial to evaluate what the effect is of evidence-based order sets aimed at five indications on the appropriateness of laboratory test ordering in primary care.
- Conditions
- Diabetes Mellitus, Hypertension, Cardiovascular Diseases, Fatigue
- Trial name
- NCT02950142
- Testing
- CPOE with order sets for lab testing, CPOE without order sets for lab testing
- Where
- Belgium
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Hypertension, Pulmonary
The Effect of Tracleer® on Male Fertility
The objective of the study is to evaluate the effects of chronic TRACLEER® treatment on testicular function via semen analysis in male patients with primary pulmonary arterial hypertension (PAH).
- Trial name
- NCT00082186
- Testing
- bosentan
- Volunteers
- 22 people
- Sponsor
- Actelion
Idiopathic Pulmonary Arterial Hypertension
Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension
Experimental data suggest that transplantation of endothelial progenitor cells (EPCs) attenuates monocrotaline-induced pulmonary hypertension in rats and dogs.
- Trial name
- NCT00372346
- Testing
- Transplantation of autologous endothelial progenitor cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang University
Hypertension, Pulmonary
Safety of Terbogrel in Patients With Primary Pulmonary Hypertension
Study to assess the safety of terbogrel during open-label, long-term treatment in medically stable or improving patients with primary pulmonary hypertension who have completed the 12-week, double-blind randomized trial of…
- Trial name
- NCT02223494
- Testing
- Terbogrel
- Volunteers
- 33 people
- Sponsor
- Boehringer Ingelheim
Asthma Bronchial
Asthma and Primary Arterial Hypertension: an Inflammatory Link?
A low-intervention, prospective, experimental study will be conducted with the overall aim of assessing the inflammatory, functional and clinical differences between patients with asthma and those with asthma and hypertension, in…
- Trial name
- NCT07903805
- Testing
- measurement of inflammatory markers
- Where
- Italy
- Volunteers
- 74 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Primary Myelofibrosis, Primary Pulmonary Hypertension
Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder
To determine the prevalence of myelofibrosis in patients with primary pulmonary hypertension, and to discover if the fibrosis in these patients is primary (AMM) or secondary.
- Conditions
- Primary Myelofibrosis, Primary Pulmonary Hypertension, Secondary Myelofibrosis, Pulmonary Arterial Hypertension
- Trial name
- NCT00722254
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Utah
Hypertension, Pulmonary
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with Pulmonary Arterial…
- Trial name
- AMBITION (NCT01178073)
- Testing
- ambrisentan, tadalafil
- Where
- 143 sites in United States, Australia and 12 more
- Volunteers
- 610 people
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension
Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension
Based on existing literature and clinical trials, 2- hydroxbenzylamine (2-HOBA) has clear impact on mechanisms that much of the international field of pulmonary hypertension (PH) research agrees are central to disease…
- Trial name
- NCT06176118
- Testing
- 2-HOBA
- Volunteers
- 12 people
- Sponsor
- Vanderbilt University Medical Center